Workflow
Task Engine
AI-generated tasks from meeting intelligence, data alerts, and PDSA cycles
4
Proposed
2
Approved
3
In Progress
3
Done
0
Rejected
Schedule prescriber outreach for top 6 Onvida oncologists
AI identified 6 prescribers responsible for 72% of referral leakage at Onvida. Recommends pharmacist-led outreach within 2 weeks to redirect scripts.
Prepare Revlimid REMS mitigation plan
Leadership standup flagged $390K/mo in 340B savings at risk from REMS changes. AI drafted a mitigation plan covering alternative formulary paths.
Deploy enhanced eligibility screening at Onvida
Remediation review identified $180K/mo in missed 340B savings due to eligibility gaps. AI recommends deploying the screening tool that achieved 94.2% rate at Memorial Hermann.
Review Cigna step therapy impact on Skyrizi patients
Payer policy change detected: Cigna new step therapy for Skyrizi affects ~120 patients. AI estimates $840K revenue at risk across portfolio.
Compile biosimilar conversion patient lists for Phase 1
Biosimilar PDSA approved. Need patient eligibility lists for Humira → Hadlima conversion across Memorial Hermann and Ascension.
Submit 2 FTE hire request for Onvida PA team
Remediation meeting approved staffing increase. HR paperwork and budget approval needed.
Present SMS PDSA study findings to Memorial Hermann QBR
Study phase shows +4.9pp adherence improvement. Prepare deck with control vs. treatment group analysis.
Deploy electronic PA templates at Michigan
Fast-track PA protocol PDSA in "do" phase. Templates built — deploying to remaining 3 departments.
Analyze Ascension payer reimbursement trends
QBR prep: compare reimbursement rates across payers for the past 4 quarters. Flag any below cost-plus-8%.
Share formulary impact analysis with Memorial Hermann
Completed: Skyrizi formulary expansion analysis showing $680K 340B savings impact delivered to Dr. Torres.
Finalize prescriber outreach list for Onvida
Completed: Top 20 prescribers identified with capture rate, leakage value, and recommended outreach approach.
Confirm Q1 revenue forecast
Completed: $48M annual run rate confirmed. Upside scenarios documented for Skyrizi expansion.